Gallardo family expand ownership of Almirall

23 May 2018
mergers-acquisitions-big

The Gallardo Family, the main shareholders of the listed Spanish pharmaceutical company Almirall (ALM: MC), today announced to the Spanish Regulator the acquisition of 8.45% of the shares of the company that were in the hands of Daniel Bravo Andreu.

This acquisition was carried out in an indirect manner through which Grupo Corporativo Landon (the business holding company of the Gallardo Family) acquired a third of the corporate structure through which Messrs. Jorge and Antonio Gallardo, together with Mr Bravo, jointly and in joint action controlled 25.34% of the shares through the company TODASA.

After this operation, Messrs. Gallardo went on to control 66.64% of the shares of Almirall, which is Spain’s largest drugmaker, and Mr Bravo keeps his shareholding in person as well as the position in the board of directors of the company; the remaining 33.1% is diversified as a Free float in the Spanish stock exchange. The Free float, therefore, does not change.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical